| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
232,140,000 |
| Market
Cap: |
1.44(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.28 - $6.93 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 15.1 |
| Insider 3/6 Months : 15.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ardelyx is a biopharmaceutical company focused on discovering, developing and commercializing medicines. This includes adult patients with irritable bowel syndrome with constipation (IBS-C), adult patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus, or hyperphosphatemia; and adult patients with CKD and/or heart failure with elevated serum potassium, or hyperkalemia. Co.'s product pipeline includes among other, IBSRELA, a sodium hydrogen exchanger 3 inhibitor for the treatment of IBS-C in adults; and XPHOZAH, which is a medicine being developed for the control of serum phosphorus in adult patients with CKD on dialysis.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
881,377 |
1,587,274 |
1,587,274 |
| Total Buy Value |
$0 |
$3,403,196 |
$6,777,784 |
$6,777,784 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
4 |
8 |
8 |
| Total Shares Sold |
165,551 |
332,360 |
747,654 |
2,414,532 |
| Total Sell Value |
$997,142 |
$1,706,165 |
$4,032,677 |
$16,289,882 |
| Total People Sold |
6 |
6 |
8 |
10 |
| Total Sell Transactions |
7 |
15 |
37 |
106 |
| End Date |
2025-06-19 |
2025-03-18 |
2024-09-17 |
2023-09-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Williams Laura A |
Chief Patient Officer |
• – – |
2025-08-26 |
4 |
S |
$6.12 |
$489,680 |
D/D |
(80,000) |
366,322 |
|
-4% |
|
| Williams Laura A |
Chief Patient Officer |
• – – |
2025-08-26 |
4 |
OE |
$0.99 |
$49,500 |
D/D |
50,000 |
446,322 |
|
- |
|
| Kelliher Mike |
Chief Business Officer |
• – – |
2025-08-21 |
4 |
S |
$5.93 |
$32,132 |
D/D |
(5,417) |
276,741 |
|
-5% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2025-08-21 |
4 |
S |
$5.93 |
$34,647 |
D/D |
(5,841) |
305,890 |
|
-5% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2025-08-21 |
4 |
S |
$5.93 |
$41,741 |
D/D |
(7,037) |
409,052 |
|
-5% |
|
| Williams Laura A |
Chief Patient Officer |
• – – |
2025-08-21 |
4 |
S |
$5.93 |
$37,138 |
D/D |
(6,261) |
396,322 |
|
-5% |
|
| Foster Eric Duane |
Chief Commercial Officer |
• – – |
2025-08-21 |
4 |
S |
$5.93 |
$90,802 |
D/D |
(15,308) |
301,498 |
|
-5% |
|
| Raab Michael |
President & CEO |
• • – |
2025-08-21 |
4 |
S |
$5.93 |
$271,002 |
D/D |
(45,687) |
1,502,250 |
|
-5% |
|
| Parsey Merdad |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
15,235 |
57,291 |
|
- |
|
| Bertrand William C Jr |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
60,941 |
290,707 |
|
- |
|
| Mott David M |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
72,714 |
2,969,585 |
|
- |
|
| Bhanji Muna |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
41,551 |
137,353 |
|
- |
|
| Cadoret-Manier Onaiza |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
41,551 |
151,701 |
|
- |
|
| Bazemore Robert B |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
41,551 |
41,551 |
|
- |
|
| Rodgers Richard J |
Director |
– • – |
2025-06-18 |
4 |
A |
$0.00 |
$0 |
D/D |
63,019 |
413,543 |
|
- |
|
| Mott David M |
Director |
– • – |
2025-06-16 |
4 |
B |
$3.63 |
$725,880 |
D/D |
200,000 |
2,896,871 |
2.39 |
75% |
|
| Mott David M |
Director |
– • – |
2025-06-09 |
4 |
B |
$3.69 |
$737,260 |
D/D |
200,000 |
2,696,871 |
2.39 |
71% |
|
| Renz Justin A |
Chief Financial Officer |
• – – |
2025-05-20 |
4 |
S |
$4.08 |
$29,460 |
D/D |
(7,218) |
416,089 |
|
-54% |
|
| Williams Laura A |
Chief Medical Officer |
• – – |
2025-05-20 |
4 |
S |
$4.08 |
$26,207 |
D/D |
(6,421) |
402,583 |
|
-54% |
|
| Foster Eric Duane |
Chief Commercial Officer |
• – – |
2025-05-20 |
4 |
S |
$4.08 |
$10,232 |
D/D |
(2,507) |
316,806 |
|
-54% |
|
| Grammer Elizabeth A |
See Remarks |
• – – |
2025-05-20 |
4 |
S |
$4.08 |
$24,456 |
D/D |
(5,992) |
311,731 |
|
-54% |
|
| Raab Michael |
President & CEO |
• • – |
2025-05-20 |
4 |
S |
$4.08 |
$191,079 |
D/D |
(46,817) |
1,547,937 |
|
-54% |
|
| Kelliher Mike |
See Remarks |
• – – |
2025-05-20 |
4 |
S |
$4.08 |
$59,270 |
D/D |
(14,522) |
282,158 |
|
-54% |
|
| Mott David M |
Director |
– • – |
2025-05-15 |
4 |
B |
$3.29 |
$329,120 |
D/D |
100,000 |
2,496,871 |
2.39 |
90% |
|
| Raab Michael |
President & CEO |
• • – |
2025-05-02 |
4 |
AS |
$4.25 |
$177,168 |
D/D |
(41,666) |
1,594,754 |
|
62% |
|
554 Records found
|
|
Page 1 of 23 |
|
|
0.23 (3.58%) 
